Flonoltinib maleate

Current understanding

To be populated as evidence accumulates.

2026-08-13 — Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors: Early-phase clinical study (trial-early) characterizes flonoltinib maleate as a highly JAK2-selective dual JAK2/FLT3 inhibitor entering safety/MTD/PK/preliminary-efficacy testing in intermediate/high-risk MF, PV, and ET, supported by preclinical data showing dose-dependent activity and lower toxicity than marketed JAK inhibitors. (novelty: 3)
2026-08-10 — Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis: Early-phase dose-finding trial comparing three daily oral dose regimens of flonoltinib maleate in adults with myelofibrosis inadequately controlled by the most common approved therapy; primary endpoints cover symptom/organ-damage control and safety, with no efficacy or adverse-event results yet reported. (novelty: 3)